CIK 0001936258 · Large accelerated filer
NewAmsterdam Pharma Co N.V.
Sign in to watch- Ticker
- NAMS
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- Netherlands
- Entity type
- operating
- Phone
- 35 206 2971
- Business address
- GOOIMEER 2-35, NARRDEN, Netherlands, 1411 DC
- Former names
- NewAmsterdam Pharma Co B.V.
Securities
- NAMS Ordinary Shares Nasdaq
- NAMSW Warrant Nasdaq
- Open-market buys, last 90 days
- $226,500
- in 1 filing
- Open-market sales, last 90 days
- $4,661,919
- in 3 filings, $4.6M under 10b5-1 plans
Net −$4,435,419. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-06-24 | Topper James N Director | Purchase | +2,520 | $18.43 | $46K | 3,024,873 |
| 2025-06-16 | Topper James N Director | Purchase | +8,584 | $19.50 | $167K | 3,022,153 |
| 2025-06-16 | Kling Douglas F Chief Operating Officer | Option exercise 10b5-1 | +78,101 | $10.00 | $781K | 122,101 |
| 2025-06-16 | Kling Douglas F Chief Operating Officer | Option exercise 10b5-1 | +21,899 | $10.90 | $239K | 144,000 |
| 2025-06-16 | Kling Douglas F Chief Operating Officer | Sale 10b5-1 | −81,891 | $19.19 | $1.6M | 62,109 |
| 2025-06-16 | Kling Douglas F Chief Operating Officer | Sale 10b5-1 | −18,109 | $19.75 | $358K | 44,000 |
| 2025-06-16 | Kling Douglas F Chief Operating Officer | Option exercise · Option (right to buy) 10b5-1 | −78,101 | 372,829 | ||
| 2025-06-16 | Kling Douglas F Chief Operating Officer | Option exercise · Option (right to buy) 10b5-1 | −21,899 | 261,314 | ||
| 2025-06-01 | Marino Michael F III See Remarks | Grant or award | +55,000 | 55,000 | ||
| 2025-06-01 | Marino Michael F III See Remarks | Grant or award · Option (right to buy) | +315,000 | 315,000 | ||
| 2025-06-01 | LANGE LOUIS G Director | Option exercise | +68 | 28,186 | ||
| 2025-06-01 | LANGE LOUIS G Director | Option exercise · Restricted Stock Unit | −68 | 0 | ||
| 2025-05-15 | Kling Douglas F Chief Operating Officer | Option exercise 10b5-1 | +100,000 | $10.00 | $1.0M | 144,000 |
| 2025-05-15 | Kling Douglas F Chief Operating Officer | Sale 10b5-1 | −100,000 | 44,000 | ||
| 2025-05-15 | Kling Douglas F Chief Operating Officer | Option exercise · Option (right to buy) 10b5-1 | −100,000 | 450,930 | ||
| 2025-05-01 | Audet Juliette Berangere See Remarks | Grant or award · Option (right to buy) | +30,000 | 30,000 | ||
| 2025-05-01 | LANGE LOUIS G Director | Option exercise | +69 | 28,118 | ||
| 2025-05-01 | LANGE LOUIS G Director | Option exercise · Restricted Stock Unit | −69 | 68 | ||
| 2025-04-15 | Kling Douglas F Chief Operating Officer | Option exercise 10b5-1 | +100,000 | $10.00 | $1.0M | 144,000 |
| 2025-04-15 | Kling Douglas F Chief Operating Officer | Sale 10b5-1 | −99,090 | 44,910 |
Page 8 of 15 · 300 trades